Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Embryonic signaling in melanoma: potential for diagnosis and therapy.

Strizzi L, Hardy KM, Kirsammer GT, Gerami P, Hendrix MJ.

Lab Invest. 2011 Jun;91(6):819-24. doi: 10.1038/labinvest.2011.63. Epub 2011 Apr 4.

2.

Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis.

Kim EK, Yun SJ, Ha JM, Kim YW, Jin IH, Yun J, Shin HK, Song SH, Kim JH, Lee JS, Kim CD, Bae SS.

Oncogene. 2011 Jun 30;30(26):2954-63. doi: 10.1038/onc.2011.22. Epub 2011 Feb 21.

PMID:
21339740
3.

Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer.

Sosa MS, Lopez-Haber C, Yang C, Wang H, Lemmon MA, Busillo JM, Luo J, Benovic JL, Klein-Szanto A, Yagi H, Gutkind JS, Parsons RE, Kazanietz MG.

Mol Cell. 2010 Dec 22;40(6):877-92. doi: 10.1016/j.molcel.2010.11.029.

4.

Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

Vigil D, Cherfils J, Rossman KL, Der CJ.

Nat Rev Cancer. 2010 Dec;10(12):842-57. doi: 10.1038/nrc2960. Epub 2010 Nov 24. Review.

5.

P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer.

Montero JC, Seoane S, Ocaña A, Pandiella A.

Oncogene. 2011 Mar 3;30(9):1059-71. doi: 10.1038/onc.2010.489. Epub 2010 Nov 1.

PMID:
21042280
6.

Translating cancer research into targeted therapeutics.

de Bono JS, Ashworth A.

Nature. 2010 Sep 30;467(7315):543-9. doi: 10.1038/nature09339.

PMID:
20882008
7.

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K.

Nature. 2010 Sep 30;467(7315):596-9. doi: 10.1038/nature09454.

8.

Inhibition of mutated, activated BRAF in metastatic melanoma.

Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB.

N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011.

9.

Integrative genome comparison of primary and metastatic melanomas.

Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M, Wu M, Scott KL, Kwong LN, Xiao Y, Cordon-Cardo C, Granter SR, Ramaswamy S, Golub T, Duncan LM, Wagner SN, Brennan C, Chin L.

PLoS One. 2010 May 24;5(5):e10770. doi: 10.1371/journal.pone.0010770.

10.

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R.

Cell. 2010 Jan 22;140(2):209-21. doi: 10.1016/j.cell.2009.12.040.

11.

Ex vivo live imaging of melanoblast migration in embryonic mouse skin.

Mort RL, Hay L, Jackson IJ.

Pigment Cell Melanoma Res. 2010 Apr;23(2):299-301. doi: 10.1111/j.1755-148X.2010.00669.x. Epub 2010 Jan 7. No abstract available.

12.

Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.

Küsters-Vandevelde HV, Klaasen A, Küsters B, Groenen PJ, van Engen-van Grunsven IA, van Dijk MR, Reifenberger G, Wesseling P, Blokx WA.

Acta Neuropathol. 2010 Mar;119(3):317-23. doi: 10.1007/s00401-009-0611-3.

13.

Melanocytes in development and cancer.

Uong A, Zon LI.

J Cell Physiol. 2010 Jan;222(1):38-41. doi: 10.1002/jcp.21935. Review.

14.

Understanding melanoma signaling networks as the basis for molecular targeted therapy.

Smalley KS.

J Invest Dermatol. 2010 Jan;130(1):28-37. doi: 10.1038/jid.2009.177.

15.

Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis.

Qin J, Xie Y, Wang B, Hoshino M, Wolff DW, Zhao J, Scofield MA, Dowd FJ, Lin MF, Tu Y.

Oncogene. 2009 Apr 23;28(16):1853-63. doi: 10.1038/onc.2009.30. Epub 2009 Mar 23.

16.

Rac1 accumulates in the nucleus during the G2 phase of the cell cycle and promotes cell division.

Michaelson D, Abidi W, Guardavaccaro D, Zhou M, Ahearn I, Pagano M, Philips MR.

J Cell Biol. 2008 May 5;181(3):485-96. doi: 10.1083/jcb.200801047. Epub 2008 Apr 28.

17.

Requirement for Rac1 in a K-ras induced lung cancer in the mouse.

Kissil JL, Walmsley MJ, Hanlon L, Haigis KM, Bender Kim CF, Sweet-Cordero A, Eckman MS, Tuveson DA, Capobianco AJ, Tybulewicz VL, Jacks T.

Cancer Res. 2007 Sep 1;67(17):8089-94.

18.

Membrane translocation of P-Rex1 is mediated by G protein betagamma subunits and phosphoinositide 3-kinase.

Barber MA, Donald S, Thelen S, Anderson KE, Thelen M, Welch HC.

J Biol Chem. 2007 Oct 12;282(41):29967-76. Epub 2007 Aug 13.

19.

Melanoma biology and new targeted therapy.

Gray-Schopfer V, Wellbrock C, Marais R.

Nature. 2007 Feb 22;445(7130):851-7. Review.

PMID:
17314971
20.

Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.

Shields JM, Thomas NE, Cregger M, Berger AJ, Leslie M, Torrice C, Hao H, Penland S, Arbiser J, Scott G, Zhou T, Bar-Eli M, Bear JE, Der CJ, Kaufmann WK, Rimm DL, Sharpless NE.

Cancer Res. 2007 Feb 15;67(4):1502-12.

Supplemental Content

Support Center